This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report.

Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision.

Title & Source: Associations of delta-9-tetrahydrocannabinol quantity and Cannabis use frequency with Cannabis use disorder among adults who use Cannabis in the United States. (Preventive Medicine, September 2026)

Lead Authors & Identifiers: Jacob T Borodovsky, Melanie Wall, Cara A Struble, Jun Liu, Alan J Budney, Deborah S Hasin. | Primary Record: DOI: 10.1016/j.ypmed.2026.108669 | PMID: 42805506 Content lane: Safety Signal.

1. Scientific & Clinical Background: In an analysis of N = 3,303 past-month adult cannabis users in the United States from the International Cannabis Policy Study (ICPS), investigators evaluated how consumed milligrams of delta-9-THC per using day and overall use frequency independently relate to cannabis use disorder (CUD) diagnosis and criteria counts.

2. Detailed Findings & Primary Data: Higher consumed mgTHC per using day significantly predicted greater odds of meeting CUD criteria (OR = 1.28, 95% CI: 1.20, 1.37) and a higher total criteria count (beta = 0.84, 95% CI: 0.61, 1.07), independent of use frequency. Frequency was also independently predictive: participants consuming on 1 to 10 days per month had markedly lower CUD odds compared with daily users (OR = 0.28, 95% CI: 0.20, 0.40). Higher mgTHC was most strongly linked to time spent, tolerance, and hazardous use criteria.

3. Dr. Caplan’s Clinical & Practical Guidance: In clinical practice, asking patients simply ‘how many days a week do you use cannabis’ misses half the clinical picture. Two patients using three days per week may have vastly different exposure profiles if one uses 5 mg oral tinctures and the other consumes 100 mg high-potency concentrates. Quantification of actual milligrams consumed is essential for personalized harm reduction.

4. Study Boundaries & Methodological Limits: These findings rely on self-reported exposure through the online Cannabis Exposure Index. While sophisticated, self-report is subject to recall bias and potency estimation errors, especially among consumers of unstandardized flower or homemade edibles.

Title & Source: Increasing cannabis use among U.S. Adults: Greater growth among historically lower-use groups, BRFSS 2016-2024. (Addictive Behaviors, September 2026)

Lead Authors & Identifiers: Ray M Merrill, Benjamin J Edvalson, Elle Crockett. | Primary Record: DOI: 10.1016/j.addbeh.2026.108863 | PMID: 42805011 Content lane: Evidence Check.

1. Scientific & Clinical Background: Evaluating data from the nationwide Behavioral Risk Factor Surveillance System (BRFSS) across 2016 through 2024, researchers assessed population-level trends in past-30-day cannabis use, specifically investigating whether groups with historically lower consumption experienced larger relative growth over the 8-year span.

2. Detailed Findings & Primary Data: Past-30-day cannabis consumption increased significantly across the US adult population, with estimated annual percent change (EAPC) demonstrating the most rapid relative growth among demographic cohorts with historically lower baseline use—notably older adults aged 65 and older, females, and individuals without prior substance use history.

3. Dr. Caplan’s Clinical & Practical Guidance: As cannabis use expands into older demographic groups, clinicians can no longer rely on conventional stereotypes about who uses cannabis. In older patients, physiological changes such as altered hepatic metabolism, polypharmacy risks, orthostatic hypotension, and fall hazards make professional clinical guidance, drug-interaction screening, and conservative micro-titration indispensable.

4. Study Boundaries & Methodological Limits: BRFSS relies on landline and cellular telephone self-reporting, which can be vulnerable to non-response bias and varying state participation across survey waves. The survey measures past-30-day frequency but does not capture product formulation, route of administration, or cannabinoid ratios.

Title & Source: Changes in Symptoms of Cannabis Use Disorder of Ontario Youth Across the COVID-19 Pandemic: A Longitudinal Cohort Study. (Substance Use & Addiction Journal, September 2026)

Lead Authors & Identifiers: Jessica Berryhill, Ian Colman, Sameer Imtiaz, Michael Chaiton, Samantha Wells, Sergio Rueda, Mina Tadrous, Hayley Hamilton, Robert Schwartz, Tara Elton-Marshall. | Primary Record: DOI: 10.1177/29767342261488975 | PMID: 42803081 Content lane: Safety Signal.

1. Scientific & Clinical Background: While youth cannabis use was known to fluctuate during the COVID-19 pandemic, long-term prospective data examining persistent changes in problematic cannabis use and CUD symptom trajectories in emerging adults remained scarce.

2. Detailed Findings & Primary Data: In a longitudinal cohort of N = 1,579 Canadian youth and young adults (aged 16 to 30, 55% female) in Ontario who reported cannabis use in the past 3 months, investigators tracked individual CUD symptoms across pre-pandemic, acute disruption, and post-restriction periods, revealing that acute surges in symptom endorsement were strongly linked to isolation and psychological distress.

3. Dr. Caplan’s Clinical & Practical Guidance: Adolescent and young adult brain development requires proactive protection against frequent, unguided high-THC exposure. When external social disruptions occur, youth frequently turn to cannabis as a self-medication coping strategy for anxiety or boredom, accelerating tolerance and dependency symptoms. Compassionate, non-punitive clinical inquiry and open communication with families are key to timely intervention.

4. Study Boundaries & Methodological Limits: The cohort was restricted to Ontario residents who already reported cannabis use at baseline, meaning findings cannot be extrapolated to non-using youth populations. Furthermore, concurrent alcohol and nicotine use and baseline psychiatric comorbidities contributed to symptom variability.

Together, these three studies reflect a critical maturation in cannabis public health literature: moving beyond binary ‘use vs. non-use’ categorization toward quantifying actual THC milligrams consumed, tracking demographic shifts in older adults, and understanding symptom trajectories during environmental disruptions.

For practicing clinicians, these publications highlight why comprehensive cannabinoid care requires evaluating patient age, baseline health status, precise cannabinoid potency, and underlying motivations for use.

From my clinical vantage point, the Borodovsky study on THC quantification is a landmark validation of what cannabinoid medicine specialists observe daily: frequency of use is only one piece of the puzzle. Consuming 5 mg of THC daily for sleep produces a completely different clinical risk profile than consuming 150 mg of high-potency concentrates three times a week. Milligram-level exposure tracking must become standard in both clinical practice and regulatory policy.

Simultaneously, the BRFSS data demonstrating rapid adoption among older adults underscores the urgent necessity of physician-guided education. When seniors explore cannabis for arthritis, insomnia, or neuropathic pain, they enter a dispensary marketplace filled with potent formulations designed for recreational tolerance. Without professional guidance on micro-dosing and drug-drug interactions, adverse events are far more likely to occur.

Three Rules for Critical Reading